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Introduction
Spirometry can indicate various lung diseases and help determine their treatment
and prognosis.1 The role of spirometry values, including forced expiratory volume in
1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FEV1/FVC), is well
established in the diagnosis, the classification of disease severity, and the prediction
of mortality for patients with COPD.2
However, the method used to define the cut-off value of airflow limitation for the
diagnosis of COPD has been debated by two groups. One group suggested that the
cut-off value of airflow limitation be defined by a fixed ratio (FEV1/FVC ,0.70 or/and
FEV1 ,80% of predicted value),3 while the other group suggested that the cut-off value
of airflow limitation by the lower limit of normal (FEV1/FVC or/and FEV1 less than the
bottom 5% percentile of normal reference value) which has the same meaning as “the
Z-score of FEV1/FVC or/and FEV1 ,-1.64”.4 In addition to both of these suggestions,
there is a third method used to define the cut-off value of airflow limitation, a spirometry
T-score. Similar to defining the T-score of bone mineral density, spirometry T-score
can be defined by the spirometry values corrected with the young age where the lung
function is at peak. Older subjects are more vulnerable to, and have poorer outcomes
due to respiratory diseases even though they may have the same spirometry values
that are expressed in spirometry Z-score.5,6 In the present study, we hypothesized that
369

submit your manuscript | www.dovepress.com

International Journal of COPD 2016:11 369–379

Dovepress

© 2016 Lee et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

http://dx.doi.org/10.2147/COPD.S96117
Powered by TCPDF (www.tcpdf.org)

Background and objective: Spirometry values may be expressed as T-scores in standard
deviation units relative to a reference in a young, normal population as an analogy to the T-score
for bone mineral density. This study was performed to develop the spirometry T-score.
Methods: T-scores were calculated from lambda-mu-sigma-derived Z-scores using a young,
normal age reference. Three outcomes of all-cause death, respiratory death, and COPD death
were evaluated in 9,101 US subjects followed for 10 years; an outcome of COPD-related
health care utilization (COPD utilization) was evaluated in 1,894 Korean subjects followed
for 4 years.
Results: The probability of all-cause death appeared to remain nearly zero until -1 of forced
expiratory volume in 1 second (FEV1) T-score but increased steeply where FEV1 T-score reached
below -2.5. Survival curves for all-cause death, respiratory death, COPD death, and COPD
utilization differed significantly among the groups when stratified by FEV1 T-score (P,0.001).
The adjusted hazard ratios of the FEV1 T-score for the four outcomes were 0.54 (95% confidence interval, 0.48–0.60), 0.43 (95% CI: 0.37–0.50), 0.30 (95% CI: 0.24–0.37), and 0.69 (95%
CI: 0.59–0.81), respectively, adjusting for covariates (P,0.001).
Conclusion: The spirometry T-score could predict all-cause death, respiratory death, COPD
death, and COPD utilization.
Keywords: spirometry, T-score, COPD
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spirometry T-score may better predict the four outcomes of
all-cause death, respiratory death, COPD death, and COPDrelated health care utilization (COPD utilization).
In this study, we developed the spirometry T-score.
In addition, we compared the three methods of the fixed ratio,
the spirometry Z-score, and T-score to answer the question
as to which method has the best prediction performance for
the four outcomes.

representative, stratified, random survey of the US population
from 8 to 80 years of age.11 For this study, we used only
the data of non-Hispanic white participants 17–80 years
of age, who completed at least three acceptable spirometry
maneuvers and also whose mortality status and height were
available (Figure S1). The spirometry methods used in the US
NHANES III have been described previously by Hankinson
et al11 and in Centers for Disease Control and Prevention.12

Methods
Overview

All-cause death, respiratory death, and
COPD death after 10 years of follow-up

We performed this study using representative samples of the
two general populations, the US and Korean. In relation to
the spirometry values, the three outcomes of all-cause death,
respiratory death, and COPD death were evaluated in 9,101
subjects followed for 10 years in the Third National Health and
Nutrition Examination Survey (US NHANES III). The fourth
outcome of COPD utilization was evaluated in 1,894 subjects
followed for 4 years in the Second Korean National Health and
Nutritional Examination Survey (Korean NHANES II).

The US NHANES III recorded all-cause deaths, which were
ascertained from a public-use-linked mortality file that contains information based on the National Death Index. Deaths
from a respiratory cause were defined by the International
Classification of Diseases (ICD) J10–J98 codes; deaths
from COPD were defined the ICD codes of J40–J47 (but not
including the asthma codes J45 or J46).

Calculation of spirometry Z-scores and
T-scores

The Kaplan–Meier survival curves for the groups stratified by their spirometry T-scores were calculated with the
log-rank test. The stratification of groups for the Kaplan–
Meier curves was determined arbitrarily, but the first level
of cut-off was determined with FEV1 T-score of -2.5,
below which the probability of all-cause death appeared to
increase steeply (Figure 1). Hazard ratios of the spirometry
T-score for death was calculated by Cox proportional hazard
analysis with adjustment for age, sex, smoking history, and
co-morbidity, including cancer, heart attack, heart failure,
and diabetes.

We developed the spirometry T-score by analogy to the
bone mineral density T-score, which is expressed in standard
deviation units relative to a reference in a young, normal
population.7 However, in addition to age, spirometry values
are also dependent on height. Therefore, taking into consideration age and height for the development of a spirometry
T-score, we used the lambda-mu-sigma (LMS) method,
where spirometry values of median (mu), coefficient of variation (sigma), and skewness (lambda) were modeled.8
For the 9,101 US subjects, we calculated spirometry
Z-scores and T-scores using look-up tables using a Microsoft
Excel (Microsoft Corporation, Redmond, WA, USA) add-in
the module, which has been developed by Stanojevic et al.9,10
The young, normal reference for FEV1 and the FEV1/FVC
ratio in the US population was the value at 23 years of age
in males and 22 years of age in females, which are the ages
when the median FEV1 is the highest.
As for the 1,894 Korean subjects, we calculated spirometry Z-scores and T-scores using Korean reference equations
developed with the LMS method (Table S1). The age of the
young, normal reference for FEV1 and the FEV1/FVC ratio,
was 19 years in males and 32 years in females for Koreans.

US NHANES III data
We used anonymous, publically available data of 9,101
subjects from the US NHANES III, which is a large,
370
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Survival curves and hazard ratios of
spirometry T-scores

COPD utilization during 4 years of
follow-up
We linked the data of 1,894 subjects that were 40 years of age
or older of the Korean NHANES II with the Korean National
Health Insurance claims (Figure S2).13 In this study, we considered that health care utilization related to COPD occurred
if a participant in KHANES II in 2001 used health care
services including any procedures, tests, or treatments with
a primary diagnosis of COPD between 2002 and 2005 based
on data from Korean National Health Insurance claims.

Statistical analyses
Statistical analyses were performed using SPSS software,
version 18.0 (SPSS Inc., Chicago, IL, USA) and SAS 9.2
(SAS Institute Inc., Cary, NC, USA). In addition, pROC
in the R 2.15.2 software package for statistical computing
International Journal of COPD 2016:11
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Figure 1 Probability of all-cause death (A–F), respiratory death (G), COPD death (H), and COPD-related health care utilization (I).
Notes: Probability of all-cause death after 10 years was shown according to FEV1 expressed in T-score, Z-score, and % of predicted value (A–C) and according to the ratio of FEV1/FVC expressed in T-score, Z-score, and the ratio itself
(D–F) in the 9,101 US subjects. Probability of respiratory death and COPD death after 10 years was shown according to FEV1 T-score (G and H) in the 9,101 US subjects. Probability of COPD-related health care utilization during 4 years
of follow-up was shown according to FEV1 T-score (I) in the 1,894 Korean subjects.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; F-U, follow-up.
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(https://www.r-project.org) was used for Delong’s method of
comparison between areas under the receiver operating characteristic (ROC) curves. To estimate Harrell’s concordance
index (c-index) from each Cox proportional hazard model, the
package ‘survival’ in R 2.15.2 was used. The 95% confidence
intervals (CI) of the c-index were computed using bootstrapping method (repetition 200 times) with R package “boot”.
The peak ages of FEV1 were selected, where the medians of
FEV1 were the maximum in the reference equation models of
the LMS method. A P-value of less than 0.05 was considered
statistically significant.

Ethics statement
This study was approved by the institutional review board
of the Asan Medical Center with the approval number
of 2011-0907. The de-indentified secondary data of US
NHANES III and Korean NHANES II are open to the public,
and no US institutional review board approval is required.

Results
Results from the analyses of the US
NHANES III

Subject characteristics of the US NHANES III
Among the 9,101 subjects, 51% were female. The mean
age was 45 years and 52% had a smoking history (Table 1).
Death from any cause occurred in 929 (10.2%) subjects
during the 10 years of follow-up. Eighty-five subjects (0.9%)
died of respiratory causes; 43 deaths (0.5%) were caused
by COPD.

Spirometry T-score for the prediction of all-cause
death, respiratory, and COPD death
The probability of all-cause death, respiratory death, and
COPD death during 10 years of follow-up appeared to
increase steeply as FEV1 T-score decreased to negative values
(Figure 1). The probability of all-cause death appeared to
remain zero or nearly zero until an FEV1 T-score of approximately -1, and this increased slowly until reaching a score
of approximately -2.5, after which the probability of death
appeared to increase steeply (Figure 1A).
For the prediction of all-cause, respiratory, and COPD
death, the prediction performance of the FEV1 T-score was
higher than that of the FEV1 Z-score or the FEV1 percent of
predicted value (P,0.001 for all comparisons; Figure 2A–C).
As for the T-score of FEV1/FVC, the prediction performance
was lower than FEV1 T-score (P,0.05 for all comparisons;
Figure 2A–C and E–G).
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Table 1 Baseline characteristics of subjects included in this
study
US subjects
9,101 (100%)

Korean subjects
1,894 (100%)

Number of subjects (%)
Age (years)
17–39
40–64
$ 65
Sex
Male
Female
Smoking status
Never smoker
Current or ex-smoker
Comorbidity
Cancer
Heart attack
Heart failure
Diabetes
Hypertension

4,092 (45.0%)
3,247 (35.7%)
1,762 (19.4%)

N/a
1,618 (85.4%)
276 (14.6%)

4,460 (49.0%)
4,641 (51.0%)

924 (48.8%)
970 (51.2%)

4,395 (48.3%)
4,706 (51.7%)

1,112* (59.9%)
745 (40.1%)

676 (7.4%)
334 (3.7%)
223 (2.5%)
605 (6.7%)
2,122 (23.5%)

N/a
N/a
N/a
N/a
N/a

Mean ± standard deviation
Spirometry values
FEV1 T-score
FEV1 Z-score
FEV1 % of predicted
value
FEV1/FVC T-score
FEV1/FVC Z-score
FEV1/FVC ratio

-1.52±1.76
-0.35±1.24
89.0±16.8

-0.83±1.26
0.21±1.10
95.0±14.6

-0.89±1.03
-0.21±0.97
0.78±0.09

-0.67±0.79
-0.26±0.86
0.78±0.08

Notes: The US subjects and Korean subjects were the participants of the Third
National Health and Nutrition Examination Survey (US NHANES III) and the Second
Korean National Health and Nutritional Examination Survey (Korean NHANES II),
respectively. *The smoking history of 37 subjects was missing.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital
capacity; N/a, not applicable.

The prediction performance of FEV1/FVC ratio itself was
comparable to that of FEV1/FVC T-score for the prediction
of respiratory death and COPD death (P=0.93 and 0.68,
respectively; Figure 2F and G), and was even higher than
that of FEV1/FVC T-score for the prediction of all-cause
death (P,0.001 for both comparisons; Figure 2E). The
prediction performance of the FEV1/FVC ratio was higher
than that of FEV1/FVC Z-score for the prediction of all-cause
death, respiratory death, COPD death, and COPD utilization
(P,0.0001 for all comparisons; Figure 2E–G).

Cut-off values of spirometry T-scores for the
prediction of all-cause death
The cut-off values of the FEV1 T-score that reached the
maximum Youden index (sensitivity + specificity -1) for the
prediction of all-cause death were -2.5 in males and -2.4 in
females. The corresponding FEV1/FVC T-scores were -1.1
in males and -1.6 in females. For the prediction of 10-year
all-cause death, an FEV1 T-score of -2.5 had a sensitivity
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Figure 2 Receiver operating characteristic (ROC) curves for the prediction of all-cause death (A and E), respiratory death (B and F), COPD death (C and G), and COPD-related health care utilization (D and H).
Notes: ROC curves for the prediction of death were shown according to FEV1 expressed in T-score, Z-score, and % of predicted value (A–C) and according to the ratio of FEV1/FVC expressed in T-score, Z-score, and the ratio itself
(E–G) in the 9,101 US subjects. ROC curves for the prediction of COPD-related health care utilization were shown according to FEV1 expressed in T-score, Z-score, and % of predicted value (D) and according to the ratio of FEV1/FVC
expressed in T-score, Z-score, and the ratio (H) in the 1,894 Korean subjects.
Abbreviations: AUC, area under curve; CI, confidence interval; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; F-U, follow-up.
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Survival curves for COPD utilization differed significantly
among the groups when stratified by FEV1 T-score (P,0.001
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0.15
0.10
0.21
0.15
0.10
0.22
0.56
0.20
0.27
0.35
0.11
0.29

0.92
0.58
0.73
0.71
0.41
0.59

0.72
0.87
0.75
0.72
0.93
0.85

0.64
0.45
0.48
0.43
0.34
0.44

0.93
0.72
0.84
0.86
0.63
0.79

0.72
0.87
0.74
0.72
0.93
0.85

0.65
0.59
0.58
0.58
0.56
0.64

0.23
0.14
0.32
0.29
0.16
0.33

0.92
0.96
0.89
0.86
0.94
0.89
0.78
0.89
0.77
0.75
0.94
0.88
0.78
0.31
0.50
0.60
0.17
0.41

Youden
index
Sensitivity
Youden
index*

Specificity

Youden
index

COPD death

Specificity

Youden
index

Sensitivity

Specificity
Sensitivity
Specificity

FEV1 T-score ,-2.5#
FEV1 , LLN‡
FEV1 ,80% of predicted value
FEV1/FVC T-score ,-1.5§
FEV1/FVC , LLN‡
FEV1/FVC ,0.70

Survival curves and hazard ratios of the FEV1 T-score

Sensitivity

The probability of COPD utilization during 4 years of
follow-up increased steeply as FEV1 T-score decreased to
negative values (Figure 1I).
For the prediction of COPD utilization, the prediction
performance of the FEV1 T-score was higher than that of the
FEV1 Z-score or the FEV1 percent of predicted value (P,0.05
for both comparisons; Figure 2D). As for the ratio of FEV1/
FVC, the prediction performance was higher than that of
FEV1/FVC T-score or Z-score for the prediction of COPD
utilization (P,0.05 for both comparisons; Figure 2H).
As for the prediction of COPD utilization, the cut-off
value of FEV1 T-score was -1.5 and this reached the maximum of Youden index (Table S2).

COPD-related health care
utilization

Spirometry T-score for the prediction of COPD
utilization

Respiratory death

Among 1,894 subjects from the Korean NHANES II data,
51% were female. The mean age was 53 years, and 40% had
a smoking history (Table 1). COPD utilization was observed
for 156 (8.2%) subjects during 4 years of follow-up.

All-cause death

Subject characteristics

Korean subjects

Results from the analyses of the Korean
NHANES II

US subjects

Survival curves for all-cause death, respiratory death, and
COPD death differed significantly among the groups when
stratified into four groups (,-4.5, -4.5 to -3.6, -3.5 to -2.6,
and $-2.5) by FEV1 T-score (P,0.001 for all log-rank tests;
Figure 3A–C).
The adjusted hazard ratios of the FEV1 T-score for
all-cause death, respiratory death, and COPD death were
0.54 (95% CI: 0.48–0.60), 0.43 (95% CI: 0.37–0.50), and
0.30 (95% CI: 0.24–0.37), respectively, adjusting for age,
sex, smoking history, and co-morbidity in the US subjects
(P,0.0001 for all Cox proportional hazard analyses).

Criteria of abnormal
spirometry

Survival curves and hazard ratios of the
FEV1 T-score

Table 2 Various criteria of abnormal spirometry for the prediction of all-cause death, respiratory death, COPD death, and COPD-related health care utilization
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of 0.78 and a specificity of 0.78, which were higher than
the indices calculated using the other criteria of abnormal
spirometry (Table 2).
For the prediction of COPD death, the FEV1/FVC ratio
with the cut-off value of 0.70 appeared to be comparable to
FEV1 T-score with the cut-off value of -2.5 (Table 2).

Notes: The sensitivity and specificity for the prediction of all-cause death, respiratory death, and COPD death after 10 years of follow-up in the US subjects and for the prediction of COPD-related health care utilization during 4 years
of follow-up in the Korean subjects. *Defined as sensitivity + specificity -1. #The cut-off values of the FEV1 T-score that reached the maximum Youden index for the prediction of all-cause death were -2.5 in males and -2.4 in females.
‡
FEV1 or FEV1/FVC , LLN (lower limit of normal, bottom 5% percentile) has the same meaning as “the Z-score of FEV1 or FEV1/FVC ,-1.64”. §The cut-off values of the FEV1/FVC T-scores that reached the maximum Youden index for
the prediction of all-cause death were -1.1 in males and -1.6 in females. We arbitrarily chose the cut-off value of -1.5 between -1.1 and -1.6. The combined data of both males and females was presented here.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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Figure 3 Kaplan–Meier survival curves for all-cause death (A), respiratory death (B), and COPD death (C) and also for COPD-related health care utilization (D).
Notes: A total of 9,101 subjects in the US (A–C) and 1,894 subjects in South Korea (D) were stratified by FEV1 T-score. All-cause death, respiratory death, COPD death,
and COPD-related health care utilization differed significantly among the four groups (P,0.001 by the log-rank tests).
Abbreviation: FEV1, forced expiratory volume in 1 second.

for log-rank test; Figure 3D). The adjusted hazard ratio
of the FEV1 T-score for COPD utilization was 0.69 (95%
CI: 0.59–0.81) adjusting for age, sex, amount smoked,
monthly income, presence of pulmonary symptoms,
and physician-diagnosed COPD in the Korean subjects
(P,0.001; Cox proportional hazard analysis).

Discussion
In this study, we developed a spirometry T-score that could
predict all-cause death, respiratory death, and COPD death
in the US population and COPD utilization in the Korean
population. This study suggests that spirometry values might
also be corrected in the same way as that of the diagnosis of
osteoporosis for which a young, normal reference is used to
determine T-scores of bone mineral density. The rationale
for using T-score might be that the age-related vulnerability
should be taken into account;5,6 the rationale for Z-scores is
that the age-related variability should be taken into account.
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We found that the probability of all-cause death appeared
to increase steeply when the FEV1 T-score decreased below
approximately -2.5 (Figure 1A). We also found that the
optimal cut-off values of the FEV1 T-score for the prediction of all-cause death were -2.5 in males and -2.4 in
females, where the Youden index reached the maximum
value. However, which cut-off value of spirometry should
be chosen might be dependent on the outcome. As for the
outcome of COPD utilization, the cut-off value of -1.5 in
FEV1 T-score was the value where Youden index was the
maximum (Table S2).
We also found that the prediction performance of FEV1/
FVC ratio itself was comparable to, or even better than
that of FEV1/FVC T-score, for the prediction of all-cause
death, respiratory death, COPD death, and COPD utilization
(Figure 2E−H). In addition, the criteria of abnormal spirometry by “FEV1/FVC ,0.70” were comparable to that by “FEV1
T-score ,-2.5” for the prediction of COPD death (Table 2).
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However, the prediction performance of FEV1/FVC Z-score
did not appear to be as good as that of FEV1/FVC ratio itself
or T-score. The prediction performance for COPD death had
a sensitivity of 0.63 and a specificity of 0.93, with a Youden
index of 0.56 given that the criterion of abnormal spirometry
was an FEV1/FVC ratio less than the lower limit of normal,
bottom 5% percentile (which has the same meaning as an
FEV1/FVC Z-score less than -1.64) (Table 2). If the criterion
FEV1/FVC ,0.70 was chosen, then the sensitivity would be
0.79 and specificity 0.85, with a Youden index of 0.64. These
results might support the definition of airflow limitation using
the FEV1/FVC criterion of less than 0.70, suggested by the
COPD clinical practice guidelines.14,15
The T-score of bone mineral density is known to reflect
future fracture risk. A recent meta-analysis found that fracture
risk increases by 1.5-fold to 2.6-fold for every unit decrease
in standard deviation of mean bone mineral density.16 In
our study, one standard deviation decrease in FEV1 T-score
increased the risk of all-cause death by 1.9 times (the reciprocal of 0.54), respiratory death by 2.3 times (1/0.43), COPD
death by 3.3 times (1/0.30), and COPD-related health care
utilization by 1.4 times (1/0.69). Therefore, FEV1 T-scores
might be comparable to T-scores of bone mineral density.
There are some limitations to discuss. First, determining
cause of death is not easy or clear, so ICD disease coding
might not be as accurate as assumed in this study. However,
the large sample size of this study would probably overcome a coding issue. In addition, ICD disease coding has
already been validated in previous studies in both US and
Korean subjects.13,17 Second, to apply these study results
to COPD patients, post-bronchodilator spirometry may be
needed, because the clinical practice guidelines of COPD
management suggest post-bronchodilator spirometry for
the diagnosis and classification of COPD. Unfortunately,
post-bronchodilator spirometry data are not available for the
general population in the US or in Korea. The importance of
post-bronchodilator spirometry may be challenged, because
the clinical significance of bronchodilator responsiveness is
not universally accepted.18 Third, this study included only
white US and Korean participants and therefore, general
application to other ethnicities can be limited. For subjects of
other ethnicities, a global lung function equation developed
by Quanjer et al19 may be of assistance. Finally, although
Youden index is used to determine which methods are superior to others, it is not always informative. The usefulness
of Youden index, also the sensitivity and specificity, are
mainly determined on the setting or the goal. For example,
the FEV/FVC ratio below the LLN would be better than the
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fixed FEV/FVC ratio in a situation where a physician would
be in the clinical context of selecting patients who are not
at risk of COPD.
Compared with the conventional diagnostic criteria of
COPD, FEV1 T-score appears to be superior in prediction
performance of important outcomes. Therefore, with the
superior prediction performance of spirometry T-score,
should we use it in clinical practice? Without a consensus of
experts or academic societies, we should be prudent to use it
in clinical practice, because a vast majority of evidences have
been built with the diagnostic criteria of FEV1/FVC with
a cut-off of 0.70 in research of COPD. Because this study
shows that the criteria FEV1/FVC of less than 0.70 works
acceptably and because spirometry T-score seems to be too
complicated to develop, we suggest that the conventional
diagnostic criteria of FEV1/FVC, with a cut off of 0.70, be
acceptable for the diagnosis of COPD in clinical practice.

Conclusion
Spirometry T-score with the age of young, normal reference
could predict all-cause death, respiratory death, COPD death,
and COPD utilization.
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Figure S1 Flow of subjects’ selection from the US NHANES III.
Abbreviation: NHANES III, Third National Health and Nutrition Examination Survey.
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XQDYDLODEOHQ 
6XEMHFWVDQDO\]HG
Q 
Figure S2 Flow of subjects’ selection from the Korean NHANES II.
Abbreviation: NHANES II, Second National Health and Nutritional Examination
Survey.

Table S1 Selection of “healthy” subjects for the development of spirometry reference values for Koreans
Reasons of exclusion
Total
History of smoking $5 packs over whole life
Physician diagnosis of respiratory diseases
Asthma
COPD
Lung cancer
Pulmonary tuberculosis
Bronchiectasis
Respiratory symptoms or limitation
Wheezing during past year
Wheezing when exercise during past year
Phlegm more than 3 months during past year
Cough more than 3 months during past year
Activity limitation d/t respiratory problem
Occupational exposure to
Noxious chemicals
Environmental pollutants
Missing values
Height and weight
FEV1

Number of
subjects excluded

Number of subjects
who remained

2,038

4,927*
2,889

111
10
0
118
14

2,778
2,768
2,768
2,650
2,636

132
68
3
0
6

2,504
2,436
2,433
2,433
2,427

72
95

2,355
2,260

7
1

2,253
2,252#

Notes: *Total number of participants for spirometry. #Final number of subjects for the development of spirometric reference equations.
Abbreviations: FEV1, forced expiratory volume in 1 second; d/t, due to.
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Table S2 Various criteria of abnormal spirometry for the prediction of COPD-related health care utilization (COPD utilization)
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Criteria* of abnormal spirometry
FEV1 T-score ,-1.5*
FEV1 Z-score ,-1.0*
FEV1 % of predicted value ,79
FEV1/FVC T-score ,-1.8*
FEV1/FVC Z-score ,-1.4*
FEV1/FVC ,0.71*

COPD-related health care utilization in the Korean subjects
Sensitivity

Specificity

Youden index#

0.50
0.31
0.31
0.24
0.21
0.37

0.74
0.90
0.90
0.92
0.92
0.87

0.24
0.20
0.21
0.16
0.12
0.24

Notes: The sensitivity and specificity for the prediction of COPD utilization during 4 years of follow-up in the Korean subjects. *The cut-off values were chosen where their
Youden indices were the maximum. #Defined as sensitivity + specificity -1.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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